Hydroxychloroquine shortages during the COVID-19 pandemic
- PMID: 32434820
- DOI: 10.1136/annrheumdis-2020-217835
Hydroxychloroquine shortages during the COVID-19 pandemic
Keywords: antirheumatic agents; autoimmune diseases; epidemiology; hydroxychloroquine; lupus erythematosus, systemic.
Conflict of interest statement
Competing interests: CT reports advisory board (Abbvie, Boehringer Ingelheim, Celgene, Lilly, Medexus/Medac, Merk, Pfizer, Sandoz), consultant (Celgene, Centocor, Medexus/Medac, Merk, Pfizer), speaker (Medexus/Medac), all outside the submitted work; SRJ reports site investigator (Bayer, Boehringer Ingelheim, Corbus, GSK, BMS), advisory board (Ikaria, Boehringer Ingelheim), all outside the submitted work.
Comment in
-
Response to: 'Hydroxychloroquine shortages during the COVID-19 pandemic' by Mendel et al.Ann Rheum Dis. 2021 Mar;80(3):e32. doi: 10.1136/annrheumdis-2020-217954. Epub 2020 May 20. Ann Rheum Dis. 2021. PMID: 32434826 No abstract available.
Comment on
-
COVID-19 and rheumatology: first steps towards a different future?Ann Rheum Dis. 2020 May;79(5):551-552. doi: 10.1136/annrheumdis-2020-217494. Ann Rheum Dis. 2020. PMID: 32299844 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical